Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx pharmacokinetics by age in female cancer patients
NL-OMON23804Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2008
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of pegylated liposomal doxorubicin in Nonhematologic neoplasms (2 cohorts), sponsored by Erasmus MC. Primary endpoint: Age-related difference in PEG DOXO AUC. Started Aug 2008; status: recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON23804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23804.